Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clini

Intellia Therapeutics (NTLA) announced positive three-year follow-up data from its Phase 1/2 study of lonvo-z, a CRISPR-based therapy for hereditary angioedema (HAE), showing a 98% mean reduction in monthly HAE attack rate and all 10 patients remaining attack-free and treatment-free for a median of 23 months. The Phase 3 HAELO trial has completed screening ahead of schedule, with topline results expected in the first half of 2026, supporting a potential BLA submission that year and a U.S. launch in 2027, positioning lonvo-z as a potential one-time treatment for HAE.

Analysis

Intellia Therapeutics (NTLA) has reported highly encouraging three-year follow-up data from the Phase 1 portion of its Phase 1/2 study for lonvoguran ziclumeran (lonvo-z), a CRISPR-based therapy candidate for Hereditary Angioedema (HAE). A single dose of lonvo-z resulted in a 98% mean reduction in monthly HAE attack rates across all 10 patients, who remained attack-free and treatment-free for a median of 23 months. Notably, deep, dose-dependent, and durable reductions in plasma kallikrein protein were observed. The therapy was well-tolerated, with a favorable safety profile; infusion-related reactions were the most frequent adverse events, primarily Grade 1 and resolved. This robust, long-term efficacy and safety data supports lonvo-z's potential as a first-in-class, one-time treatment for HAE, addressing a significant unmet medical need. Further bolstering confidence, the global Phase 3 HAELO trial has completed screening ahead of schedule, with over half of participants from U.S. sites. Intellia anticipates reporting topline results from this pivotal trial in the first half of 2026, with plans for a Biologics License Application (BLA) submission in 2026 aiming for a U.S. launch in 2027. New and longer-term data from the Phase 2 portion of the study is expected in the second half of 2025, which will provide further insights.

Key Decisions for Investors

• The sustained efficacy demonstrated over three years, particularly the 98% attack reduction and prolonged attack-free period, significantly strengthens the clinical and commercial prospects of lonvo-z, warranting a positive outlook on Intellia's HAE program.
• Investors should monitor key upcoming catalysts, including the Phase 2 data update in H2 2025 and the pivotal Phase 3 HAELO trial results in H1 2026, which are critical inflection points for the asset's valuation and regulatory pathway progression.
• Given the potential for lonvo-z to become a one-time curative therapy, its market positioning could be highly disruptive; however, inherent clinical development, regulatory approval, and market adoption risks associated with novel gene editing therapies should be carefully considered in investment theses.